On June 27, 2018 Oxford Vacmedix, the UK based biopharma company focused on the development of a new generation of cancer vaccines, reported that its novel Recombinant Overlapping Peptide (ROP) technology had been presented at the 2018 Myongji International Cancer Symposium .
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The meeting was held in Seoul, South Korea and focused on new horizons in the development of treatments for cancer on immunotherapy and on precision medicine. Other speakers included researchers from the MayoClinic and the University of Chicago in the US as well as from St Luke’s International hospital in Japan.
Dr. Jiang, CSO and Founder of Oxford Vacmedix (OVM) and a researcher in the Department of Oncology at University of Oxford, presented the role of TNF as a potential target for cancer therapy and the exciting preclinical data of OVM’s leading development programmes for two Cancer vaccines. OVM-100 is an HPV vaccine targetedat cervicalcancer,and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Bothvaccines are being developed as single agents and in combination with immuno-oncology agents. The company will also continue to develop its diagnostic kits for cellular immunity.
William Finch, CEO of Oxford acmedix said: "We were very pleased to present ROP technology at this important meeting and to have the opportunity to discuss the novel research and the exciting development programme which could lead to significant benefit for patients with cancer"
Wang-Jun Lee, Chairman of Myongji Hospital Group, added: "We are delighted DrJiang could participate in this meeting and we look forward to a productive collaborations with OVM especially in research and in clinical trials. We are confident that we can support the continued growth and development of the company"